FDA

Roche Secures Key US Approval for New Oral Leukaemia Treatment

The US Food and Drug Administration (FDA) has approved a new oral combination therapy for chronic lymphocytic leukaemia developed by Genentech, a US subsidiary of Swiss pharmaceutical giant Roche, offering a new time-limited, non-chemotherapy option for patients.